This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Top Research Reports for Costco, Altria & Edwards Lifesciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale (COST), Altria Group, Inc. (MO), and Edwards Lifesciences (EW).
Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised
by Zacks Equity Research
Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.
Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 86.32% and 17.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad (BIO)-Seegene Pact to Provide Diagnostic Suit In U.S.
by Zacks Equity Research
Bio-Rad (BIO) and Seegene team up to develop and commercialize molecular diagnostic products in the United States.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 108.40% and 9.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BioRad (BIO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher (TMO) Gets EUA for Amplitude/TaqPath COVID-19 Kit
by Zacks Equity Research
Thermo Fisher's (TMO) Amplitude Solution is likely to allow clinical and public health laboratories to process up to 8,000 samples in a single day with the help of minimum workforce.
Thermo Fisher (TMO) Rides on End Markets as Pandemic Rages On
by Zacks Equity Research
In diagnostics and healthcare, Thermo Fisher (TMO) is experiencing high demand for COVID-19 testing and manages to record 200% growth.
Medtronic's (MDT) GI Genius Module Gets FDA De Novo Clearance
by Zacks Equity Research
Medtronic's (MDT) GI Genius Module is the only commercially available computer-aided detection system which uses artificial intelligence to identify colorectal polyploid.
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Logitech, Harley-Davidson, Fulgent Genetics, Bio-Rad Laboratories and IDEXX Laboratories highlighted as Zacks Bull and Bear of the Day
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal second-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
CVS Health (CVS) Extends COVID-19 Testing in Massachusetts
by Zacks Equity Research
CVS Heath's (CVS) antibody testing to be available in nearly 60 MinuteClinic locations and cost $38.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies and robust testing portfolio.
Why Is Bio-Rad (BIO) Down 13% Since Last Earnings Report?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Makes Bio-Rad Laboratories (BIO) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Bio-Rad Laboratories (BIO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Bio-Rad Laboratories (BIO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 29.35% and 15.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Feb 11 Earnings Roster: DXCM, LH & More
by Trina Mukherjee
The Medical Product companies' fourth-quarter results are likely to reflect huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.